Gilead Sciences (GILD) Upgraded by CIBC to “Outperform”

CIBC upgraded shares of Gilead Sciences (NASDAQ:GILD) from a market perform rating to an outperform rating in a research report report published on Thursday, January 3rd. The brokerage currently has $85.00 price objective on the biopharmaceutical company’s stock.

Several other equities research analysts have also weighed in on the stock. BidaskClub lowered shares of Gilead Sciences from a buy rating to a hold rating in a research note on Wednesday, November 21st. ValuEngine raised shares of Gilead Sciences from a sell rating to a hold rating in a research report on Saturday, December 1st. Cantor Fitzgerald reissued an overweight rating and issued a $92.00 price target on shares of Gilead Sciences in a research report on Wednesday, December 19th. Zacks Investment Research lowered Gilead Sciences from a buy rating to a hold rating in a research note on Monday, December 31st. Finally, Evercore ISI reiterated a buy rating on shares of Gilead Sciences in a report on Wednesday, October 31st. Ten investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of Buy and a consensus target price of $88.39.

NASDAQ:GILD opened at $68.16 on Thursday. The stock has a market capitalization of $87.89 billion, a price-to-earnings ratio of 7.96, a PEG ratio of -2.35 and a beta of 1.06. The company has a debt-to-equity ratio of 1.09, a current ratio of 3.45 and a quick ratio of 3.37. Gilead Sciences has a 1-year low of $60.32 and a 1-year high of $89.54.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, October 25th. The biopharmaceutical company reported $1.84 EPS for the quarter, topping the consensus estimate of $1.63 by $0.21. Gilead Sciences had a net margin of 7.12% and a return on equity of 39.32%. The company had revenue of $5.60 billion during the quarter, compared to the consensus estimate of $5.44 billion. During the same quarter last year, the firm posted $2.27 EPS. As a group, sell-side analysts expect that Gilead Sciences will post 6.44 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Friday, December 28th. Investors of record on Friday, December 14th were given a dividend of $0.57 per share. The ex-dividend date was Thursday, December 13th. This represents a $2.28 dividend on an annualized basis and a yield of 3.35%. Gilead Sciences’s dividend payout ratio (DPR) is 26.64%.

In related news, Director John C. Martin sold 50,000 shares of the company’s stock in a transaction on Monday, December 3rd. The shares were sold at an average price of $71.20, for a total transaction of $3,560,000.00. Following the completion of the sale, the director now directly owns 2,877,762 shares of the company’s stock, valued at approximately $204,896,654.40. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 1.16% of the stock is currently owned by corporate insiders.

Institutional investors have recently modified their holdings of the company. Gamco Investors INC. ET AL boosted its holdings in Gilead Sciences by 15.4% during the second quarter. Gamco Investors INC. ET AL now owns 14,980 shares of the biopharmaceutical company’s stock worth $1,061,000 after buying an additional 2,000 shares in the last quarter. Bridgewater Associates LP bought a new position in shares of Gilead Sciences during the 2nd quarter valued at $3,706,000. Senvest Management LLC acquired a new position in Gilead Sciences in the 2nd quarter valued at $4,959,000. Lcnb Corp acquired a new position in Gilead Sciences in the 2nd quarter valued at $310,000. Finally, BTG Pactual Global Asset Management Ltd grew its stake in Gilead Sciences by 12.7% in the 2nd quarter. BTG Pactual Global Asset Management Ltd now owns 9,525 shares of the biopharmaceutical company’s stock valued at $675,000 after buying an additional 1,071 shares during the last quarter. Institutional investors and hedge funds own 78.01% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.

Read More: Risk Tolerance

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply